Cutaneous melanoma · line 1 · Dabrafenib + trametinib (BRAF V600E+ NSCLC)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	aggressive
Linked regimen	`REG-DABRAFENIB-TRAMETINIB-NSCLC`

ID	`IND-MELANOMA-BRAF-METASTATIC-1L-DABRA-TRAME`
Type	Indication
Status	status not declared
Diseases	`DIS-MELANOMA`
Sources	`SRC-COMBI-D-LONG-2014` `SRC-ESMO-MELANOMA-2024` `SRC-NCCN-MELANOMA-2025`

Notes

Reuses cross-disease BRAF V600E doublet REG-DABRAFENIB-TRAMETINIB-NSCLC.

Used By

Algorithms

ALGO-MELANOMA-METASTATIC-1L - ALGO-MELANOMA-METASTATIC-1L

Handbook Chapters

HB-MELANOMA-METASTATIC-1L - Metastatic melanoma: BRAF / IO first-line reasoning

Handbook Questions

HQ-MELANOMA-MET-1L-002 - HQ-MELANOMA-MET-1L-002